Combined antiretroviral therapy with nevirapine of HIV-infected adults


如何引用文章

全文:

作者简介

A Kravchenko

参考

  1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, <http://www.hiatis.org> (accessed 4 February 2002).
  2. Nelson M. The role of NNRTls in antiretroviral combination therapy: an introduction. Int. J. STD and AIDS 2001; 12 (suppi. 4): 1-2.
  3. Van Leeuwen R. The Atlantic Study: A randomized, open-label trial comparing two protease inhibitor (Pl)-sparing antiretroviral strategies versus a standard Pi-containing regimen, 2 year follow-up data. In: XIV International AIDS conference. Barcelona; 2002. abstr. MoPeB3089.
  4. Podzamczer D. Final 12-month results from the COMBINE study: A randomized, open, multicenter trial comparing Combivir plus nelfinavir or nevirapine in naive Patients. 1st IAS conference on HIV pathogenesis and treatment. July 8-11, 2001. Buenos Aires. Buenos Aires; 2001. In: oral abstr. 7.
  5. Pollard R. and the 1090 Team. Factors predictive of durable HIV suppression in a randomized double blind trial with nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS. In: 7"' Conference on retroviruses and opportunistic infections. San Francisco; 2000. abstr. 517.
  6. Mackie N., Sabin C., Weston R. et al. Durability and tolerability of nevirapine-containing regimens in a cohort of antiretroviral-naive HIV-positive patients. In: XIV International AIDS conference. Barcelona; 2002. abstr. TuPeB4443.
  7. Кравченко А. В., Саламов Г. Г., Богословская Е. В. и др. Трехкомпонентная комбинированная антиретровирусная терапия с применением ингибиторов обратной транскриптазы ВИЧ. Эпидемиол. и инфекц. бол. 2001; 4: 32- 35.
  8. Arribas J. Comparison of NNRTls in antiretroviral-na'ive patients. Int. J. STD and AIDS 2001; 12 (suppl. 4): 3-9.
  9. van Leth F., Hassink E., Phanuphak P. et al. Results of the 2NN study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: 10th Conference on retroviruses and opportunistic infections. February 10-14, 2003, Boston, Massachusetts. Boston; 2003. abstr. 176.
  10. Maggiolo F. Comparison of NNRTls in antiretroviral-expirienced patients. Int. J. STD and AIDS 2001; 12 (suppl. 4): 10-17.
  11. Negredo E., Cruz L., Paredes R. et al. Virological, immunological and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin. Infect. Dis. 2002; 34: 504-510.
  12. Hicks C., Brun S., King M. et al. Kaletra (Lopinavir/Ritonavir) therapy in single protease inhibitor experienced patients 144 week follow up. In: 8th ECAATH, 2001. Athens; 2001. abstr. P220.
  13. Khana N., Klimkait Т., Schiffer V. et al. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor or heavily pre-treated HIV-1 infected patients. Swiss HIV cohort study. AIDS 2000; 14: 791-799.
  14. Gymez A., Ncez M., Soriano V. et al. Toxicity of antiretroviral therapy (ART). 9 years experience. In: 7th ECAATH. Lisbon;1999. abstr. 577

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2004

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house